Results 251 to 260 of about 3,108,169 (356)

A Real-World Evaluation of Clinical Prognostic Scores in Advanced Melanoma Treated with Immune Checkpoint Inhibitors. [PDF]

J Clin Med
Yildiran Keskin GS, Karadurmus N.
europepmc   +1 more source

Use of Oncept melanoma vaccine in 69 canine oral malignant melanomas in the United Kingdom [PDF]

, 2017
Bateman, Bergin, Bergman, Bergman, Blackwood, Boria, Bostock, Boston, Brockley, Dank, Esplin, Freeman, Grosenbaugh, Hahn, Harvey, Kosovsky, Liao, Modiano, Murphy, Nguyen, Ottnod, Pires, Proulx, Ramos-Vara, Rassnick, Smedley, Smith, Spangler, Théon, Treggiari, Tuohy, Wallace, Williams   +32 more
core   +3 more sources

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Prognostic Biomarkers for Anti-PD-1 Monoclonal Antibodies in the First Line Treatment of Advanced Melanoma. [PDF]

Int J Dermatol
Pásek M, Marques E, Tretera V, Arenberger P, Arenbergerová M, Šilar J, Šulc D.   +6 more
europepmc   +1 more source

Cold atmospheric plasma‐mediated tumor microenvironment remodeling for cancer treatment

BMEMat, EarlyView.
Schematic presentation of CAP‐mediated TME remodeling. This review summarizes recent efforts in cold atmospheric plasma (CAP) application in cancer treatment, highlighting the anticancer potential of CAP, molecular mechanisms, and future perspectives for further improvement and clinical translation.
Israr Khan, Qiujie Fang, Cao Fei, Ziyuan Wang, Zhaowei Chen, Guojun Chen, Zhiming Xu, Shu Xu, Zhitong Chen   +8 more
wiley   +1 more source

Late-Onset Immune-Related Adverse Events in Patients with Advanced Melanoma: The LATENT Study. [PDF]

Cancers (Basel)
Pozas J, Cheruvu S, Jaganathan PP, Ganesan P, Modi A, Larkin J, Cossar L, Olsson-Brown A, Johnson A, Garbutt N, Lee R, Jones J, Macklin-Doherty A, Young K, Latent Study Investigators.   +14 more
europepmc   +1 more source

Advancing design strategies in smart stimulus‐responsive liposomes for drug release and nanomedicine

BMEMat, EarlyView.
Schematic illustration of stimulus‐responsive liposomes designed for controlled drug release and nanomedicine. The innermost circle represents different liposomal structures, including unilamellar, multilamellar, and multivesicular liposomes. The middle layer illustrates the responsive phospholipid components.
Yuchen Guo, Nan Li, Daiwei Zhang, Jingya Gu, Zhihuan Liao, Zihao Teng, Xiangfu Du, Peter S. Timashev, Shipeng Chen, Shuaidong Huo   +9 more
wiley   +1 more source

Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047. [PDF]

Clin Cancer Res
Lipson EJ, Dolfi S, Tang H, Tawbi HA, Medina-Soto F, Castillo Gutiérrez E, Rutkowski P, Gogas H, Murillo E, Ascierto PA, Desai K, Maio M, Demers K, Mazzei A, Keidel S, Miller-Moslin K, Yu JX, Hodi FS, Schadendorf D, Long GV, Garnett-Benson C.   +20 more
europepmc   +1 more source

Nanomaterials‐mediated glycolysis rewriting to potentiate tumor immunotherapy

BMEMat, EarlyView.
This review systematically summarizes cutting‐edge advances in glycolysis‐rewiring nanomedicines, emphasizing their mechanisms in reversing immunosuppression and reinvigorating antitumor immune responses. Challenges in clinical translation and future directions for designing multifunctional metabolic‐immune modulators are also critically discussed ...
Zilin Ma, Songyan Li, Jie Yan, Xuechun Wang, Wen Zhao, Yunxuan Song, Dongdong Liu, Jianwei Jiao, Xiuying Duan, Guiqiang Zhang   +9 more
wiley   +1 more source

Efficacy and safety of CTLA-4, PD-1 and LAG-3 immune checkpoint inhibitors as monotherapy and combination therapy in advanced melanoma: A systematic review and meta-analysis. [PDF]

EXCLI J
Omar Khan O.
europepmc   +1 more source